Emergent BioSolutions to Engage in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) recently announced that key members from its management team will be engaging with investors at various upcoming investor conferences. This engagement aligns with the company's ongoing commitment to transparency and investor relations, ensuring that stakeholders are updated about the company's direction and accomplishments.
Key Events on the Horizon
The first notable event is the Wells Fargo 20th Annual Healthcare Conference, set for September 4, 2025, at 3:00 PM ET. Participants from Emergent will be available for one-on-one meetings, providing an opportunity for investors to discuss the company's innovative strategies and vision.
Webcast and Presentations
Investors can partake in a webcast of this presentation, with a convenient access link provided ahead of the event to ensure a seamless experience.
Following this, on September 9, 2025, Emergent will present at the HCW 27th Annual Global Investment Conference at 1:30 PM ET. This conference also offers the chance for one-on-one meetings, a testament to Emergent's dedication to investor communication.
Connecting with Investors
Emergent encourages stakeholders to reach out to their conference representatives for one-on-one meeting requests. This is part of their effort to reinforce relationships with current investors and forge new ones, highlighting the company’s robust position in the healthcare sector.
Accessing Live Presentations
For those unable to attend, all presentations and recorded sessions will be available on the Emergent Investor Relations Page. This feature allows investors to stay up-to-date with the latest insights even if they cannot attend live sessions, further promoting transparency.
Understanding Emergent BioSolutions' Mission
Emergent BioSolutions has been at the forefront of public health for over 25 years. Their mission is crucial—to protect and save lives through the delivery of life-saving solutions addressing serious health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose. This commitment reflects their integrity and dedication to public health nationwide.
Innovative Solutions for Health Threats
The company remains active in developing products that effectively manage public health emergencies, a role they take seriously amid evolving health challenges. Their proactive approach ensures communities are well-prepared for both current and future threats, a hallmark of their operational strategy.
Investor and Media Contacts
Emergent BioSolutions prioritizes communication with investors. For inquiries, investors can connect with Richard S. Lindahl, Executive Vice President and CFO, via email at lindahlr@ebsi.com. Additionally, media inquiries can be directed to Assal Hellmer, Vice President of Communications, reachable at mediarelations@ebsi.com.
Frequently Asked Questions
What is the purpose of the investor conferences?
The investor conferences allow Emergent BioSolutions to communicate directly with investors about their strategic plans and innovations.
How can I access the presentations from the conferences?
Presentations and replays will be available on Emergent's Investor Relations Page for those who cannot attend the live sessions.
Who should I contact for one-on-one meetings during the conferences?
Investors can reach out to their conference representative to arrange one-on-one meetings.
How long has Emergent BioSolutions been in operation?
Emergent BioSolutions has been protecting public health for more than 25 years.
What health threats does Emergent BioSolutions address?
The company provides solutions for health threats including smallpox, mpox, botulism, Ebola, and opioid overdose emergencies.
